Back To Schedule
Wednesday, June 21 • 10:30am - 11:45am
#316: Quantitative Metrics to Capture the Value of Patient Engagement

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Component Type: Session
Level: Intermediate
CE: ACPE 1.25 Knowledge UAN: 0286-0000-17-569-L04-P; CME 1.25; IACET 1.25; RN 1.25

There is growing agreement among stakeholders in the medical products life cycle that patient engagement is key to assuring that patient needs, including improved patient outcomes, are met. The moral, ethical, and pragmatic reasons for patient engagement are widely accepted, but research sponsors must understand the impact of patient engagement on the performance of important studies and are often faced with the need to demonstrate its value before allocating resources, both personnel and financial, to implementation. Understanding return on investment, or “return on engagement (ROE),” is complicated by the availability of many different types of patient engagement efforts that could be employed and the lack of information about their value in a given context.

Presenters in this session will discuss the results of recent projects aimed at defining metrics, both quantitative and qualitative, to assess the value of patient engagement in the medical products life cycle.

Learning Objectives

Discuss the results of recent projects aimed at defining metrics, both quantitative and qualitative, to assess the value of patient engagement in the medical products life cycle.


Kenneth A. Getz, MBA


Defining Metrics for ROE of Patient-Centric Initiatives Across the Product Life Cycle
Stella Stergiopoulos, MPH, MS

Getting Down to the Bottom Line: Measuring the Financial Impact of Patient Engagement
Bennett Levitan, MD, PhD

Update on the PFMD: Landscape of Patient-Centric Initiatives
Marc M. Boutin, JD

avatar for Marc Boutin

Marc Boutin

Chief Executive Officer, National Health Council (NHC)
Marc M. Boutin, JD, is the Chief Executive Officer of the National Health Council. He has been a leading voice for greater patient involvement at every stage of the health care continuum. Boutin has been actively involved in patient advocacy organization management, health advocacy... Read More →
avatar for Kenneth Getz

Kenneth Getz

Executive Director/Professor, Tufts CSDD; Founder/Board Chair, CISCRP, Center For the Study of Drug Development, United States
Ken Getz is the Executive Director and a Professor at the Tufts Center for the Study of Drug Development, Tufts University School of Medicine. He is also the chairman of CISCRP – a nonprofit organization that he founded to educate and raise public and patient awareness of the clinical... Read More →
avatar for Bennett Levitan

Bennett Levitan

Senior Director, Benefit-Risk Assessment, Global Epidemiology, Janssen , United States
Bennett Levitan, MD-PhD is Senior Director, Global R&D Epidemiology at Janssen R&D. He introduced state of the art patient-focused benefit-risk (B-R) assessment to Janssen and his team has led numerous clinical teams in B-R assessments and patient preference studies. He co-led development... Read More →
avatar for Stella Stergiopoulos

Stella Stergiopoulos

Research Fellow, Tufts Center for the Study of Drug Development
Ms. Stella Stergiopoulos leads multi-sponsored research projects at Tufts CSDD. She has experience conducting research on pharmaceutical industry practices and trends affecting pharmacovigilance, non-clinical drug development, pharmaceutical outsourcing practices, cycle time metrics... Read More →

Wednesday June 21, 2017 10:30am - 11:45am CDT
N426a McCormick Place 2301 South Martin Luther King Jr. Drive, Gate 4 Chicago, IL 60616
  04: PatientEngagement, Session